The management of Castleman disease
Oliver Lomas(Johnson & Johnson (United States)), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Daniel Royston(John Radcliffe Hospital), Matthew Streetly(King's College - North Carolina), Stephen Schey(University College Hospital), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Jim Cavet(University of Manchester)
Cited by 28
Related Papers
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315
Guidelines for the diagnosis and management of multiple myeloma 2011
|British Journal of Haematology|2011|305
Zn, Cu and Co in cyanobacteria: selective control of metal availability
|FEMS Microbiology Reviews|2003|294